Article
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
Leukemia - 1 Sept 2013
Allen C, Hills R K, Lamb K, Evans C, Tinsley S, Sellar R, O'Brien M, Yin J L, Burnett A K, Linch D C, Gale R E
Abstract excerpt
Several different mutations collaborate with the fusion proteins in core-binding factor acute myeloid leukemia (CBF-AML) to induce leukemogenesis, but their prognostic significance remains unclear. We screened 354 predominantly younger (<60 years) adults with t(8;21) (n=199) or inv(16) (n=155) entered into UK MRC trials for KIT, FLT3 tyrosine kinase domain (FLT3(TKD)), N-RAS, K-RAS and c-CBL mutations and FLT3...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.